Vivani Medical, Inc. · NASDAQ:VANI
Vivani Medical — Second Sight Medical Products — Investor Presentation (January 2015)
23 slides from Vivani Medical's investor presentation, Jan 13, 2015
Slide 1: Investor Presentation January 2015
Nasdaq : EYES Investor Presentation NASDAQ: EYES January 2015
Slide 2: Forward Looking Statements
Nasdaq : EYES Forward Looking Statements This presentation contains certain forward - looking information about Second Sight that is intended to be covered by the safe harbor for "forward - looking statements" provided by the Private Securities Litigation Reform Act of 1995 , as amended . Forward -
Slide 3: Second Sight's Technology Platform
Nasdaq : EYES Second Sight ’ s Technology Platform 3 Second Sight’s Purpose : Restoring vision to the blind CNN Video: 'Bionic eye' lets blind man 'see' again http:// edition.cnn.com /video/data/2.0/video/international/2014/06/18/ spc - vital - signs - roger - pontz - bionic - eye.cnn.html
Slide 4: Second Sight's Technology Platform
Nasdaq : EYES Second Sight ’ s Technology Platform 4 Second Sight’s Purpose : Restoring vision to the blind YouTube Video: First Implant at Duke Eye Center https://www.youtube.com/watch?v=CiyGOUHD2nI
Slide 5: Corporate Summary
Nasdaq : EYES 5 Corporate Summary • Restoring vision to the blind with the Argus II platform technology • Targeting significant addressable market of over 8 million people • Commercial stage – FDA, Canada, EU, & Turkey r egulatory approvals • Strong financial position – • Successful IPO in November
Slide 6: Significant Addressable Markets
Nasdaq : EYES Significant Addressable Markets 6 8 million patients globally are legally blind due to unpreventable causes 39 million people worldwide are legally blind
Slide 7: The Argus II System – A 25 Year Journey
Nasdaq : EYES 7 Argus II Implant Argus II Glasses Video Processing Unit (VPU) The Argus ® II System – A 25 Year Journey System bypasses dead photoreceptors and stimulates underlying neurons Processes video and transforms into instructions for implant Miniature video camera captures scene Communicati
Slide 8: Experienced Management and Board
Nasdaq : EYES Experienced Management and Board Robert Greenberg Alfred E. Mann President, Chief Executive Officer & Director Chairman of the Board of Directors & Founder • Co - managed the Alfred E. Mann Foundation • Served as lead reviewer for IDEs and 510(k)s at the Office of Device Evaluation at
Slide 9: Drivers of Mass Adoption
Nasdaq : EYES Drivers of Mass Adoption 9 R&D Regulatory Environment Reimbursement Centers of Excellence Scalability
Slide 10: R&D and Regulatory Milestones
Nasdaq : EYES 10 AMD Cortical prosthesis Software upgrade 2014 2015 2016 2017 2013 AMD First enrollment in feasibility study AMD Complete enrollment in feasibility AMD First enrollment in pivotal study AMD Complete enrollment in pivotal study Cortical First mechanical model animal implants Cortical
Slide 11: R&D: Software Upgrades
Nasdaq : EYES R&D: Software Upgrades 11 From Bonham and Litvak , “ Current Focusing and Steering, ” Hearing Research 242 (2008), 141 - 153. Resolution enhancement without adding electrodes • Controlling the relative stimulation applied to adjacent electrodes can produce spatial patterns of stimulati
Slide 12: R&D: Expanding into AMD
Nasdaq : EYES R&D: Expanding into AMD Experimental work conducted in Armand Tanguay Jr. ’ s lab at USC indicated simulations with retinal prostheses in AMD patients may: • Improve time to grasp a target object and ability to avoid obstacles to grasping a target • Improve functional depth task perfor
Slide 13: R&D: Expanding into Direct Cortical Stimulation
Nasdaq : EYES R&D: Expanding into Direct Cortical Stimulation 13 Objective: bypass the optic nerve and directly stimulate the visual cortex Risks mitigated: • Orion I requires relatively minor modifications to the Argus II device • Direct cortical stimulation to restore vision previously demonstrate
Slide 14: U.S. Reimbursement
Nasdaq : EYES U.S. Reimbursement 14 • Argus II candidates are primarily Medicare Beneficiaries • In the U.S. many reimbursement objectives have been met: • Medicare codes for the device and surgical procedure (CPT, ICD - 9 - CM, HCPCS) • Transitional pass - through payment from Medicare for the devi
Slide 15: European Reimbursement
Nasdaq : EYES 15 Currently in place In process (24 + months) Not yet sought In process (12 – 24 months) European Reimbursement
Slide 16: Implanting Centers Worldwide
Nasdaq : EYES North America Kellogg – Univ . Michigan Univ . Southern California Toronto Western Hospital Wills Eye – Philadelphia Duke Eye Center Texas Retina Assoc . – Dallas Bascom Palmer – Univ . Miami Wilmer – Johns Hopkins Emory University Univ . Illinois Chicago Mayo Clinic – Minnesota German
Slide 17: Facilities and Manufacturing
Nasdaq : EYES Facilities and Manufacturing • State of the art manufacturing facility located in Sylmar, California • 10,000 square feet of controlled environment rooms (CERs). • Current capacity: ~1200 units / year 17 10 devices / month • Current manufacturing capacity • Utilizing half the space • C
Slide 18: Patent Protection
Nasdaq : EYES Patent Protection We solved five very difficult technical problems that to our knowledge no other company has solved . Our patent portfolio contains a large number of claims covering these solutions: 18 Other challenges, 178 grants and applications Reliable long lived miniature electro
Slide 19: Competitive Landscape
Nasdaq : EYES Competitive Landscape Regulatory Approval Commercialized Limitations CE FDA ✔ ✖ ✖ • Most devices reported to fail within 3 - 9 months post - implant • 8 hour surgical procedure • Requires clear eye optics and cannot be easily adapted to cortical stimulation ✖ ✖ ✖ • Employs optical data
Slide 20: Major Awards & Recognition
Nasdaq : EYES Major Awards & Recognition 20
Slide 21: Investment Highlights
Nasdaq : EYES 21 Investment Highlights • Restoring vision to the blind with the Argus II platform technology • Targeting significant addressable market of over 8 million people • Securing our market leading position with strong patent protection • Ensuring first mover advantage as the only device wi
Slide 22: Contact
Nasdaq : EYES Contact Retail Investor Relations Matt Hayden Chairman MZ North America Direct: 949 - 259 - 4986 Matt.Hayden@mzgroup.us Second Sight Medical Products, Inc. 12744 San Fernando Road Building 3 Sylmar, CA 91342 Direct: 818 - 833 - 5000 www.secondsight.com Institutional Investor Relations
Slide 23: Second Sight Medical Products – Everyone Should Have Vision
Nasdaq : EYES Second Sight Medical Products Everyone Should Have Vision TM 23
Second Sight Medical Products — Investor Presentation (January 2015) on 6ix